Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2022

View Archived Issues

AMG-794, a CLDN6-targeting BiTE for treating lung and ovarian tumors

CDK4/6 inhibitor PRT-3645 prolongs survival in glioblastoma and brain-metastatic breast cancers

TNIK as novel therapeutic target in lung squamous cell carcinoma

ZLD-2218, a novel BRD4 inhibitor for the treatment of kidney fibrosis

Discovery of novel oridonin analogues as potent anticancer agents

BeiGene patents new MAP4K1 inhibitors

Duality Biologics divulges new ADCs for cancer

Shenzhen Salubris Pharmaceuticals presents GLP-1 receptor agonists

Jiangsu Chia Tai Tianqing Pharmaceutical researchers synthesize new AKT inhibitors

Origo Biopharma discloses new TGFBR1 inhibitors

Turnstone Biologics collaborates with University of Montreal for development of TIL therapy

Portage, NCI and Stimunity collaborate to advance STING agonists and anti-RAGE agents

AI Therapeutics acquires EntreChem's EC-8042 for pediatric cancers

Targeting CD166 overcomes platinum resistance in ovarian cancer

ViGeneron and Daiichi Sankyo enter follow-on collaboration for gene therapy for eye diseases

PAK4 inhibition enhances anti-PD-1 therapy in prostate cancer

Researchers develop gene-editing platform to edit mitochondrial DNA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...